Formulation and Drug Delivery, Parenterals

A variety of strategies have been employed to deliver proteins and peptides in improved parenteral formulations and/or via noninvasive routes.

A new study proposes a new way to potentially treat congenital diseases in utero.

West will showcase several drug-delivery systems and packaging component technologies such as its NovaPure plungers and SmartDose technology platform.

Aptar Pharma has signed a license agreement with BD to jointly develop and bring a new autoinjector to market.

Experts discuss the key considerations in the development of an autoinjector.

For successful partnerships, it’s important to take a long-term view, focus on simple designs, and address potential payer concerns up front.

Capacity expansions and new products meet needs for inhaler and injector systems.

Parenteral drug delivery offers a variety of challenges but also opportunities. The author examines recent developments in nanotechnology-based drug delivery and other advances in injection-based drug delivery.

Oval Medical Technologies, an autoinjector company based in Cambridge, UK, reported that a variety of highly viscous solutions have been successfully delivered through a 25-gauge thin-wall needle, in less than 7 seconds, using its innovative autoinjector. The technology provides solutions to problems in the industry for drug containment and the end user.

Engineering nanoparticles with optimal properties for use in cancer therapies.

The author discusses potential opportunities to improve the patient experience through formulation and delivery device technologies.

The author details the factors in formulation design, requirements in facilites and equipment, and validation criteria for aseptic formualtions.

Two types of hydrogels used in parenteral protein-delivery systems offer opportunities for achieving a variety of prolonged- and delayed-release patterns.